Developing a new treatment to prevent and treat inflammation-related colon cancer
Official title: Prevention and Therapy of Inflammation Associated Colorectal Cancer
Funded at Albert Einstein College of Medicine · NIH-11024638 · Data updated 2026-11-12
This study is testing a new drug called MTDIA to see if it can help prevent and treat colon tumors caused by inflammation, using special mouse models that act like human colon cancer, with the hope of finding safer treatment options for people with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $235,620 |
| NIH project number | 1R21CA295643-01 |
| Project ID | NIH-11024638 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a history of inflammatory bowel disease or those at high risk for developing colorectal cancer.
✕Less likely to help
Patients with non-inflammatory causes of colorectal cancer or those who do not have any form of bowel inflammation may not benefit from this research.
What this research studies
This research focuses on creating a new drug called MTDIA, which targets a specific enzyme involved in the metabolism of certain compounds in the body. The study aims to evaluate how effective MTDIA and its improved versions are in preventing and treating colon tumors linked to inflammation. Using innovative mouse models that mimic human colon cancer, researchers will assess the drug's ability to inhibit tumor growth without causing toxicity. The findings could lead to new therapeutic options for patients with inflammation-associated colorectal cancer.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that effectively prevents and treats colorectal cancer associated with inflammation.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting metabolic pathways in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Augenlicht, Leonard H — Albert Einstein College of Medicine
- Study coordinator: Augenlicht, Leonard H
Related research
Other NIH-funded projects on the same topics.
-
Improving colorectal cancer screening and follow-up care.
This study is working to help more people get screened for colorectal cancer and receive the follow-up care they need, especially those who haven't been screened much before, so that everyone can have better access to important health checks and improve their overall health.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
Ceramides and how they affect metabolism and colorectal cancer in adults
A study in adults with obesity-related health issues will explore how a fat-related molecule called ceramide influences metabolic problems and colorectal cancer risk.
-
Automated point-of-care DNA methylation test for colorectal cancer in LMICs
A fast, affordable blood test using DNA markers to help identify people at higher risk of colorectal cancer in low- and middle-income countries.
-
Rewiring Colorectal Cancer to Harness Therapeutic Hyperactivation
A Yale team is exploring brain-storming new ways to treat colorectal cancer by safely boosting certain cancer signaling pathways to kill cancer cells and by reshaping cancer cell states to improve responses to existing therapies.
-
Comparative modeling to guide colorectal cancer screening and care
A researcher team will use computer models to study how access to care, risk, and new screening options affect colorectal cancer outcomes and costs for adults in the US.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.